Ibutilide for Atrial Fibrillation and Flutter Cardioversion

Ibutilide is an intravenous antiarrhythmic drug used to quickly convert abnormal heart rhythms, specifically atrial fibrillation and atrial flutter, back to a normal sinus rhythm. Sold under the brand name Corvert, it works faster than most competing drugs and is especially effective against atrial flutter, where conversion rates run between about 50 and 70 percent. Because it carries a real risk of triggering a dangerous rhythm disturbance called torsade de pointes, it is given only in monitored settings where a defibrillator and trained staff are immediately available.

How Ibutilide Restores Normal Rhythm

Most drugs that treat irregular heart rhythms work by blocking potassium channels, which slows the electrical reset of heart cells and helps stabilize the rhythm. Ibutilide does some of that, but it also activates a slow, late-phase inward sodium current, a mechanism that is fairly unusual among antiarrhythmics. The combined effect lengthens the time each heart cell takes to recharge electrically, which interrupts the rapid, chaotic signaling loops that sustain atrial fibrillation and flutter.

One advantage of ibutilide over several older antiarrhythmics is that it does not show “reverse use-dependence,” a quirk where a drug works well when the heart rate is slow but loses effectiveness when the heart is beating fast. Studies measuring the electrical action potential in human atrial and ventricular tissue found that ibutilide prolonged that potential by a similar amount regardless of whether the pacing rate was fast or slow.¹ That consistency matters because the whole point of using the drug is to intervene when the heart is beating too fast.

Efficacy for Atrial Flutter Versus Atrial Fibrillation

Ibutilide is substantially better at terminating atrial flutter than atrial fibrillation. In a large randomized trial, conversion to sinus rhythm occurred in about 63 percent of flutter cases but only 31 percent of fibrillation cases.² Those numbers held up across multiple controlled trials, with flutter conversion rates generally ranging from 50 to 70 percent and fibrillation conversion rates falling between roughly 30 and 50 percent.³

Speed is one of ibutilide’s selling points. About 80 percent of the arrhythmias that do convert do so within 30 minutes from the start of the infusion.⁴ The standard dosing protocol is a 1 mg infusion given over 10 minutes, followed by a second 1 mg dose if the first one does not work. That rapid turnaround makes it attractive in emergency departments and electrophysiology labs, where prolonged drug infusions complicate patient flow.

The gap in effectiveness between flutter and fibrillation reflects the nature of the two arrhythmias. Flutter typically involves a single, organized electrical circuit looping around the right atrium, so a drug that slows conduction through that circuit can break it. Fibrillation involves multiple disorganized wavelets, which are harder for any single drug to extinguish at once.

The Torsade de Pointes Problem

The most serious risk of ibutilide is torsade de pointes, a specific type of polymorphic ventricular tachycardia that can degenerate into cardiac arrest. Because ibutilide lengthens the electrical recovery period of heart cells, it can occasionally push that recovery time past a tipping point where the ventricles start firing erratically. In a pooled analysis of roughly 1,500 patients, about 4 percent developed torsade de pointes, with most episodes occurring during or within 45 minutes of the infusion.⁵

That rate differs between men and women. In the same analysis, roughly 5.6 percent of women developed torsade compared with 3 percent of men.⁶ The sex difference is not unique to ibutilide; women have slightly longer baseline cardiac electrical intervals on average, which puts them closer to the threshold where drugs that further lengthen those intervals can tip over into arrhythmia. This is one of the reasons clinicians screen patients carefully before giving the drug, checking baseline electrolyte levels and cardiac intervals on an ECG.

When torsade does occur, it is usually manageable if the medical team is prepared. Intravenous magnesium is the first-line treatment, and in refractory cases, electrical cardioversion can terminate the arrhythmia. In one study of patients on background class IC antiarrhythmic therapy who received ibutilide, one patient developed non-sustained polymorphic ventricular tachycardia (successfully treated with IV magnesium) and another developed sustained torsade that was terminated with a direct-current shock.⁷ The standard protocol calls for continuous ECG monitoring for at least four hours after the infusion ends, specifically because most dangerous episodes arise within that window.

Why Magnesium Makes Ibutilide Safer and More Effective

Giving magnesium before or alongside ibutilide is one of the more striking findings in the literature, because it appears to simultaneously reduce the risk of torsade de pointes and improve conversion rates. In a study comparing ibutilide alone against ibutilide plus high-dose intravenous magnesium, the group receiving magnesium converted at a rate of about 77 percent, compared with roughly 67 percent without it. More strikingly, ventricular arrhythmias occurred in about 7 percent of the ibutilide-only group but just 1.2 percent of the magnesium group, and torsade de pointes developed in about 3.5 percent of the no-magnesium group versus zero percent when magnesium was given.⁸

A separate study found a similar pattern: magnesium co-administration boosted the chemical cardioversion rate by about 19 percent and reduced the need for backup electrical cardioversion by about 34 percent.⁹ The magnesium was well tolerated even at high doses. Magnesium stabilizes cell membranes and makes it harder for the ventricle to develop the erratic after-depolarizations that trigger torsade, so the mechanism makes physiological sense. Despite this evidence, routine magnesium co-administration is not yet universally adopted, and practice varies between hospitals.

Ibutilide as a Bridge to Electrical Cardioversion

One of the most useful roles for ibutilide is not as a standalone treatment but as a pretreatment before electrical cardioversion, where a controlled shock resets the heart rhythm. In a randomized trial, patients who received ibutilide before the shock converted at a 100 percent rate, compared with 72 percent for patients who received the shock alone. The ibutilide group also needed less energy to convert, requiring about 166 joules on average compared with 228 joules without pretreatment.¹⁰

This “ibutilide-first, shock-if-needed” approach is especially valuable for patients whose arrhythmia has resisted electrical cardioversion on its own, or when clinicians want to avoid repeated high-energy shocks. The lower energy requirement also means less discomfort for the patient and potentially less myocardial stunning from the shock itself. Cost-effectiveness modeling has supported this sequential strategy, finding that starting with ibutilide and then proceeding to electrical cardioversion only for patients who do not convert is less expensive overall than going straight to electrical cardioversion as a first-line approach.¹¹

Ibutilide Compared With Amiodarone

Amiodarone is the most commonly used IV antiarrhythmic for atrial fibrillation worldwide, so it is the natural comparator. Head-to-head data paint a nuanced picture. In a study of patients with recent-onset atrial fibrillation and flutter, ibutilide converted 80 percent of patients versus 57 percent for amiodarone. The advantage was almost entirely driven by flutter cases, where ibutilide converted 87 percent compared with only 29 percent for amiodarone. For atrial fibrillation alone, the two drugs were statistically similar, at 77 versus 69 percent.¹²

In a different setting, after coronary artery bypass surgery, the two drugs performed similarly. Ibutilide reached a 24-hour conversion rate of about 95 percent and amiodarone about 88 percent, a gap that was not statistically meaningful.¹³ The practical tradeoff between the two drugs often comes down to speed and setting. Ibutilide works in minutes but requires close cardiac monitoring and carries the torsade risk. Amiodarone acts over hours and has a broader side-effect profile with long-term use (thyroid, liver, and lung toxicity), but in a single-dose acute scenario it does not carry the same torsade risk. For a patient with pure atrial flutter who needs rapid conversion, ibutilide is hard to beat.

Patients Already on Antiarrhythmic Drugs

A common clinical scenario is a patient whose atrial fibrillation or flutter breaks through despite being on a standing antiarrhythmic medication. Using ibutilide in these patients introduces potential drug interactions, but the available evidence is reassuring in some combinations. In patients on long-term amiodarone, ibutilide converted about 39 percent of atrial fibrillation cases and 54 percent of flutter cases within 30 minutes of infusion.¹⁴ Those numbers are somewhat lower than the rates seen in drug-naive patients, which makes sense because arrhythmias that persist despite amiodarone tend to be more entrenched.

In patients on class IC agents such as flecainide or propafenone, ibutilide has also been used, though the combination requires extra caution. Class IC drugs slow conduction velocity in the heart, and adding ibutilide’s action potential prolongation on top of that creates a more complex electrophysiological situation. Serious arrhythmias occurred in two out of 52 patients in one study, both of which were successfully treated.¹⁵ The general principle is that adding ibutilide to a patient already on another antiarrhythmic should be done with heightened monitoring rather than avoided entirely.

What Predicts Whether Ibutilide Will Work

Not every patient responds, and several factors have been identified that shift the odds. The size of the left atrium is one of the strongest predictors. A dilated left atrium means the atrial tissue has remodeled, creating more substrate for maintaining the arrhythmia. One review found that the conversion rate dropped to about 30 percent when the left atrium exceeded 5 cm in diameter, compared with roughly 85 percent in patients with a normal-sized atrium and no mitral valve disease.¹⁶ Mitral valve disease, which itself tends to cause atrial enlargement, independently reduced conversion rates.

The duration of the arrhythmia matters as well. In a study of ibutilide use during catheter ablation of persistent atrial fibrillation, patients who converted successfully had a shorter average arrhythmia duration of about 35 months compared with about 67 months in those who did not convert. Lower body weight and a smaller left atrial diameter also favored successful conversion.¹⁷ These findings align with what clinicians observe more broadly: the longer an arrhythmia has been present and the more the heart has remodeled in response, the harder it is for any drug to restore normal rhythm.

Pharmacokinetics and How the Body Clears It

Ibutilide is given only intravenously, and the body distributes it widely and quickly outside the bloodstream. It is cleared rapidly through the liver, which breaks it down into eight metabolites, only one of which has any meaningful cardiac activity. The elimination half-life is generally in the range of three to six hours.¹⁸ That relatively short half-life is a double-edged feature: the drug’s effects wear off within hours, which limits the window for torsade risk but also means ibutilide offers no ongoing rhythm maintenance.

In patients with heart failure due to weakened left ventricular function, no dose adjustment appears necessary. A pharmacokinetic study comparing heart failure patients with those who had normal heart function found no significant differences in peak drug concentration, total drug exposure, distribution volume, or clearance rate.¹⁹ That said, heart failure patients are at elevated baseline risk for ventricular arrhythmias, so the monitoring during and after infusion may need to be more vigilant even though the drug levels themselves are unchanged.

Use in Congenital Heart Disease

Atrial arrhythmias are extremely common in people who have had surgery for congenital heart defects, because surgical scars in the atria create the electrical circuits that drive flutter and fibrillation. Ibutilide has been studied in this population, where about 80 percent of the treated arrhythmias were atrial flutter. In a cohort of 53 patients (average age about 28 years) who underwent a total of 105 chemical cardioversions, the overall success rate was about 70 percent with a mean dose of about 1.5 mg. Adverse effects occurred after about 8 percent of administrations, with three-quarters of those events occurring in women, consistent with the sex-related risk pattern seen in adults without congenital disease.²⁰

These findings suggest that ibutilide remains a viable option in the congenital heart population, though the altered cardiac anatomy and prior surgical scarring create unique electrophysiological challenges. The decision to use it versus proceeding directly to electrical cardioversion or catheter ablation depends on the specific anatomy, the type of arrhythmia circuit, and the patient’s hemodynamic stability.

Emergency Department Use and Hospital Costs

Because ibutilide works so quickly, it fits well into emergency department workflows for patients who arrive with new-onset atrial fibrillation or flutter and are hemodynamically stable. In one protocol that used ibutilide as the first step and then electrical cardioversion for patients who did not convert, 92 percent of patients were discharged within a median of 9 hours and managed as outpatients afterward.²¹ That rapid discharge contrasts with patients who are admitted for rate-control strategies or overnight observation before planned cardioversion.

The cost picture depends on the perspective. From a hospital’s internal accounting, the drug itself costs more than simply proceeding to electrical cardioversion (about $280 versus $138 per patient in one analysis). But from the broader payer perspective, which accounts for the total cost of the hospital encounter, using ibutilide first saved roughly $324 per patient because it shortened stays and reduced the resources spent on electrical cardioversion procedures.²² The stepped approach, trying the drug first and reserving the shock for those who do not respond, consistently comes out as the most cost-effective strategy in modeling studies.²³

When Ibutilide Is Not the Right Choice

Several situations make ibutilide a poor fit. Patients with a prolonged QTc interval on their baseline ECG (generally above 440 milliseconds) face heightened torsade risk and are typically excluded. Low serum potassium or magnesium raises the same concern, so electrolytes should be corrected before the infusion. Ibutilide is also not appropriate for patients who are hemodynamically unstable from their arrhythmia, since those patients need immediate electrical cardioversion rather than waiting even 10 minutes for a drug infusion.

Patients with severe structural heart disease, particularly those with very poor ventricular function, present a judgment call. The pharmacokinetics are not altered by heart failure, as noted earlier, but the vulnerable myocardium is more susceptible to ventricular arrhythmias. The drug’s labeling and most institutional protocols allow its use in these patients but with heightened monitoring and a lower threshold to abort the infusion if the QTc starts climbing.

Long-standing persistent atrial fibrillation, lasting more than a year or two, is another scenario where ibutilide is unlikely to succeed. The predictors data show that longer arrhythmia duration and larger atrial size both dramatically reduce conversion rates.²⁴ In practice, for arrhythmias present for many months, most electrophysiologists would either proceed directly to electrical cardioversion or consider catheter ablation rather than relying on ibutilide alone.

Ibutilide During Catheter Ablation

A newer application of ibutilide is during catheter ablation procedures for atrial fibrillation. After the ablation lesions have been delivered, the electrophysiologist may give ibutilide to see whether the atrial fibrillation can still be sustained. If the drug converts the rhythm, it provides some confidence that the ablation was effective. If the arrhythmia persists despite ibutilide, it suggests that additional ablation may be needed. In one study examining this approach, the factors predicting whether ibutilide would convert the rhythm during ablation were the same ones that predict success in other contexts: shorter arrhythmia duration, smaller left atrium, and lower body weight.²⁵ Successful ibutilide conversion during the procedure was also associated with lower rates of arrhythmia recurrence after the ablation, raising the question of whether it could serve as a prognostic marker during the procedure itself.